| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Janus kinase 2 | 0.385 | 0.885 | 0.65 |
|
group | 0.500 | None | 0.975 | 527 | 6 | 2005 | 2020 | ||||||||
|
ABL proto-oncogene 1, non-receptor tyrosine kinase | 0.432 | 0.923 | 1.00 |
|
group | 0.200 | None | 0.988 | 173 | 0 | 1996 | 2020 | ||||||||
|
calreticulin | 0.413 | 0.923 | 0.89 |
|
group | 0.500 | None | 1.000 | 114 | 2 | 2013 | 2020 | ||||||||
|
MPL proto-oncogene, thrombopoietin receptor | 0.510 | 0.692 | 4.1E-09 |
|
group | 0.500 | None | 1.000 | 89 | 3 | 1996 | 2020 | ||||||||
|
BCR activator of RhoGEF and GTPase | 0.431 | 0.885 | 0.99 |
|
group | 0.500 | None | 0.976 | 82 | 0 | 1979 | 2019 | ||||||||
|
fibroblast growth factor receptor 1 | 0.362 | 0.885 | 1.00 |
|
group | 0.400 | None | 0.975 | 38 | 0 | 1998 | 2018 | ||||||||
|
platelet derived growth factor receptor beta | 0.416 | 0.846 | 0.90 |
|
group | 0.200 | None | 1.000 | 26 | 0 | 2000 | 2019 | ||||||||
|
tet methylcytosine dioxygenase 2 | 0.458 | 0.808 | 4.3E-54 |
|
group | 0.100 | None | 1.000 | 26 | 1 | 2009 | 2019 | ||||||||
|
sterol O-acyltransferase 1 | 0.424 | 0.846 | 7.4E-10 |
|
group | 0.100 | None | 1.000 | 23 | 0 | 2006 | 2020 | ||||||||
|
fms related receptor tyrosine kinase 3 | 0.462 | 0.654 | 0.61 |
|
group | 0.100 | None | 0.952 | 21 | 0 | 2002 | 2019 | ||||||||
|
platelet derived growth factor receptor alpha | 0.415 | 0.808 | 1.00 |
|
group | 0.200 | None | 1.000 | 18 | 0 | 2003 | 2019 | ||||||||
|
Janus kinase 1 | 0.474 | 0.769 | 1.00 |
|
group | 0.100 | None | 0.933 | 15 | 0 | 2010 | 2019 | ||||||||
|
ETS variant transcription factor 6 | 0.477 | 0.731 | 0.97 |
|
group | 0.100 | None | 1.000 | 14 | 0 | 1995 | 2018 | ||||||||
|
factor interacting with PAPOLA and CPSF1 | 0.575 | 0.577 | 0.79 |
|
group | 0.100 | None | 1.000 | 13 | 0 | 2003 | 2018 | ||||||||
|
zinc finger MYM-type containing 2 | 0.599 | 0.654 | 0.67 |
|
group | 0.400 | None | 1.000 | 11 | 0 | 1998 | 2016 | ||||||||
|
Cbl proto-oncogene | 0.527 | 0.769 | 6.1E-04 |
|
group | 0.100 | None | 1.000 | 10 | 0 | 2009 | 2015 | ||||||||
|
protein tyrosine phosphatase non-receptor type 11 | 0.385 | 0.923 | 1.00 |
|
group | 0.100 | None | 1.000 | 10 | 2 | 2005 | 2018 | ||||||||
|
SH2B adaptor protein 3 | 0.527 | 0.692 | 1.0E-04 |
|
group | 0.200 | None | 1.000 | 10 | 0 | 2010 | 2017 | ||||||||
|
RUNX family transcription factor 1 | 0.425 | 0.808 | 0.65 |
|
group | 0.200 | None | 1.000 | 10 | 0 | 1997 | 2014 | ||||||||
|
KIT proto-oncogene, receptor tyrosine kinase | 0.366 | 0.808 | 0.98 |
|
group | 0.090 | None | 1.000 | 9 | 3 | 2001 | 2019 | ||||||||
|
ASXL transcriptional regulator 1 | 0.482 | 0.808 | 1.3E-14 |
|
group | 0.090 | None | 1.000 | 9 | 0 | 2011 | 2019 | ||||||||
|
suppressor of cytokine signaling 3 | 0.434 | 0.808 | 0.75 |
|
group | 0.080 | None | 1.000 | 8 | 1 | 2008 | 2019 | ||||||||
|
signal transducer and activator of transcription 5A | 0.445 | 0.808 | 1.00 |
|
group | 0.080 | None | 1.000 | 8 | 0 | 2010 | 2019 | ||||||||
|
thrombopoietin | 0.513 | 0.692 | 0.20 |
|
group | 0.180 | None | 1.000 | 8 | 0 | 1995 | 2020 | ||||||||
|
GATA binding protein 1 | 0.483 | 0.808 | 0.95 |
|
group | 0.200 | None | 1.000 | 7 | 0 | 2003 | 2020 |